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Abstract  Cancer  of  the  bladder  is  the  seventh  most  common  of  all  cancers  observed  in  France,
and is  the  second  urological  cancer  after  prostate  cancer.  It  is  mainly  related  to  nicotine  addic-
tion. When  doing  the  initial  tests,  ultrasound  examination  of  the  bladder  can  enable  the  clinician
to diagnose  a  polypoid  tumour  and  thus  avoid  his  having  to  organise  diagnostic  ﬁbroscopy.  When
the bladder  tumour  inﬁltrates  the  detrusor  muscle,  the  situation  becomes  life-threatening
for the  patient  and  radical  treatment  is  envisaged.  Uro-CT  is  the  standard  examination  to
characterise  the  lesion  and  describe  its  relationship  with  neighbouring  organs.  It  is  essential,
and must  be  performed  before  endoscopic  resection  of  the  tumour,  to  be  correctly  interpreted.
It is  imperative  for  imaging  to  look  for  a  synchronous  lesion  in  the  upper  urinary  tract  (ureters,
renal pelvis),  because  the  presence  of  such  a  lesion  changes  the  prognosis  of  the  disease  and
the sequence  of  therapy,  which  is  decided  by  the  urologist  in  a  multidisciplinary  consultation.
© 2012  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Each  year,  throughout  the  world,  a  bladder  carcinoma  is  diagnosed  or  treated  in  2.7  million
people,  and  urothelial  tumours  appear  in  the  majority  of  cases  when  an  individual  is  in  his
or  her  60s  [1].  In  France,  this  disease  rates  seventh,  taking  all  cancers  into  account  (INVSS
2008),  and  is  the  second  commonest  urological  cancer  after  prostate  cancer.  Carcinoma
of  the  bladder  is  responsible  for  3%  of  deaths  from  cancer;  its  incidence  is  increasing  by
approximately  1%  per  year,  but  mortality  speciﬁcally  from  this  disease  seems  to  be  reducing
in  men  [2—4]. It  is  strongly  recommended  nowadays  to  use  the  designation  non-muscle
invasive  bladder  cancer  (NMIBC)  for  superﬁcial,  non  muscle-invasive  tumours  and  muscle
invasive  bladder  cancer  (MIBC)  where  there  is  indeed  tumour  inﬁltration  of  the  detrusor
[5]  (Table  1).  At  the  time  of  initial  diagnosis,  75  to  85%  of  tumours  are  NMIBC;  60  to  70%
E-mail address: morgan.roupret@psl.aphp.fr.
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Table  1 Classiﬁcation  of  tumours  of  the  bladder.
T  stage  Description  Name
pTa Variable  grade  papillary  tumour
without  inﬁltration  of  the
subepithelial  connective  tissue
NMIBC
pTis High  grade  ﬂat  tumour  without
inﬁltration  of  the  subepithelial
connective  tissue
pT1  Variable  grade  papillary  tumour
with  inﬁltration  of  the
subepithelial  tissue  but  without
inﬁltration  of  the  muscle
≥pT2  Tumour  invading  at  least  the
muscle
MIBC
NMIBC: non-muscle invasive bladder cancer; MIBC: muscle invasive
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Trans-urethral  resection  of  the  bladder
Resection  of  NMIBC  must  be  as  deep  and  complete  as
possible.  Histopathological  analysis  will  determine  the  the-
rapeutic  sequence.  It  is  not  possible  with  CT  to  assess
whether  a urothelial  tumour  has  inﬁltrated  the  bladder  wall.ladder cancer.
f  lesions  will  recur  in  the  ﬁrst  year  and  10  to  20%  will
rogress  to  become  invasive  and/or  metastatic  tumours  [6].
reventing  superﬁcial  tumours  is  based  on  combating  the
ain  risk  factors  of  smoking  and  exposure  in  the  industrial
orkplace  to  chemical  carcinogens  [7].  In  contrast,  upper
rinary  tract  urothelial  carcinoma  (UUT-UC)  is  much  rarer,
ith  an  incidence  of  one  to  two  cases  per  100,000  inhabi-
ants  and  per  year  [8,9]. The  aim  of  this  paper  is  to  offer
lariﬁcation  concerning  the  place  of  imaging  in  the  diagnos-
ic  process  and  in  the  management  of  urothelial  tumours.
iagnosis of bladder tumours
ymptoms
acroscopic,  often  terminal,  haematuria  is  the  most  fre-
uently  encountered  clinical  symptom.  Signs  of  bladder
rritation  (pollakiuria,  imperative  micturition,  urinary  burn-
ng)  are  observed  in  20%  of  cases.  As  long  as  there  is  no
rinary  infection,  these  symptoms  should  lead  one  to  sus-
ect  a  bladder  carcinoma  in  situ. Clinical  examination  is
imited  to  pelvic  palpation  during  which  the  extent  of  frozen
elvis  can  be  assessed  if  there  is  an  invasive  tumour  [1].
araclinical examinations for diagnosis
rinary  cytology
rinary  cytology:
detects  high  grade  tumour  cells  with  very  high  speciﬁcity;
its  sensitivity  is  low  for  low  grade  tumours;
its  interpretation  depends  greatly  on  the  doctor  who  per-
forms  it.
Positive  urinary  cytology  can  indicate  the  presence  of  a
umour  anywhere  in  the  urinary  tract  [1,9]. Cytology,  along
ith  cystoscopy,  is  still  one  of  the  standard  examinations
or  detecting  and  monitoring  NMIBC,  particularly  high  grade
nes.
D
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maging  examinations
ltrasound  examination
uprapubic  ultrasound  is  an  indispensable  examination,
hich  can  provide  the  clinician  with  certain  items  of  infor-
ation  [10]:
its  sensitivity  is  61%  to  84%  for  polypoid  tumours  larger
than  5  mm;
for differential  diagnosis,  the  presence  of  clots  (which
are  mobile,  with  no  Doppler  vascularisation,  and  can  be
fragmented  by  pressure  from  the  probe)  is  signiﬁcant;
indication  for  endorectal  ultrasound:  obese  patient  and
empty  bladder;
a  negative  ultrasound  examination  does  not  mean  cys-
toscopy  can  be  avoided.
It  is  essential  for  the  lesions  to  be  mapped  as  accurately
s  possible.  It  will  show  the  number  of  tumours,  their  topog-
aphy  relative  to  the  prostatic  urethra  and  to  the  ureteral
eatus,  their  size  and  their  appearance  (pedicled  or  ses-
ile).  When  the  patient  is  referred  with  an  ultrasound  image
ighly  suggestive  of  a  tumour  of  the  bladder,  the  diagnos-
ic  cystoscopy  stage  before  endoscopic  resection  is  optional
1].
T  examination
T  is  usually  reserved  for  staging,  in  particular  of  MIBC
efore  radical  surgery.  On  the  other  hand,  CT  can  be  very
seful  for  eliminating  an  associated  lesion  of  the  upper
rinary  tract.  In  this  indication,  the  uro-scan  is  nowadays
he  reference  examination  (in  hyperdiuresis  in  the  excre-
ory  phase)  and  therefore  replaces  intravenous  urography
11—15].
iagnostic  endoscopy
iagnosis  of  bladder  tumours  depends  mainly  on  the
ndoscopy  examination  and  the  histological  examination  of
he  entire  resected  lesion.  Fibroscopy  clariﬁes  the  num-
er  of  foci,  size,  topography  and  appearance  of  the  tumour
nd  the  appearance  of  the  mucosa  of  the  bladder,  and  is
sually  performed  under  local  anaesthesia.  However,  when
he  patient  is  referred  with  an  ultrasound  that  conﬁrms
he  diagnosis  of  a  bladder  tumour,  there  is  no  need  for
he  diagnostic  cystoscopy  stage  before  endoscopic  resec-
ion,  which  the  urologist  can  then  immediately  schedule
or  his  patient  in  the  operating  theatre.  As  for  virtual
olonoscopy  in  gastroenterology,  there  are  a  certain  num-
er  of  imaging  teams  that  are  working  on  virtual  cystoscopy
nd  virtual  ureteroscopy,  but  this  work  is  still  in  the  very
arly  stages.eep  resection  of  a  bladder  lesion  is  still  the  best  method
or  staging  parietal  inﬁltration  in  bladder  cancer.
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Looking  for  bone  metastasis
Bone  scintigraphy  is  not  systematically  indicated  in  MIBC,
but  is  still  the  ﬁrst-line  examination  if  there  is  a clinical
symptom.  Suspect  foci  should  be  checked  by  conventional
radiology,  or  better,  by  CT.  If  there  is  still  any  doubt,  a  CT-
guided  puncture  biopsy  should  be  envisaged  as  a  last  resort.
Histopathological diagnosis
Diagnosis  of  NMIBC  implies  analysing  all  the  resected  mate-
rial.  The  cell  grade  and  tumour  stage  are  the  two  basic
criteria  for  later  management.  The  current  reference  sys-
tem  for  grading  urothelial  tumours  is  the  WHO  classiﬁcation
2004  (Boxed  text  1)  [1].
Diagnosing upper urinary tract urothelial
carcinoma
UUT-UC  are  discovered  either  due  to  clinical  symptoms  or
while  staging  a  bladder  tumour  (Boxed  text  2)  [22]. In  a  third
of  cases,  UUT-UC  are  multifocal,  and  in  2  to  8%  of  cases,
bilateral.  Less  than  10%  of  UUT-UC  have  a  synchronous  blad-
der  lesion,  the  most  common  site  being  around  the  meatus.
Boxed  text  1 TNM  classiﬁcation  2002.  Tumours  of
the  bladder.
T  Primary  tumour
Tx  Primary  tumour  cannot  be  assessed
T0  No  evidence  of  primary  tumour
Ta  Non-invasive  papillary  carcinoma
Tis  Carcinoma  in  situ:  ﬂat  tumour
T1  Tumour  invades  subepithelial  connective  tissue
T2  Tumour  invades  muscularis  propria
pT2a  Tumour  invades  superﬁcial  muscularis  propria
(inner  half)
pT2b  Tumour  invades  deep  muscularis  propria  (outer
half)
T3  Tumour  invades  perivesical  tissue
pT3a  Microscopic  invasion
pT3b  Macroscopic  extravesical  invasion
T4  Tumour  invades  a  neighbouring  structure
T4a  Tumour  invades  prostatic  stroma,  vagina  or
uterus
T4b  Tumour  invades  pelvic  or  abdominal  wall
N  Regional  lymph  nodes
Nx  Lymph  nodes  cannot  be  assessed
N0  No  regional  lymph  node  metastasis
N1  Single  lymph  node  metastasis  ≤  2  cm  and  ≤  5  cm
or  multiple  lymph  node  metastases  ≤  5  cm
N3  Lymph  node  metastasis  >  5  cm
M  Distant  metastasesTumours  of  the  bladder:  What  does  the  urologist  expect  from
Paraclinical examinations for staging
CT  examination
For  NMIBC,  staging  using  CT  is  not  systematic,  but  is  all  the
more  justiﬁed  when  the  tumour  is  high  grade  or  of  consid-
erable  volume,  since  there  is  a  risk  of  under-staging.
For  MIBC,  CT  is  the  standard  examination  [15—17]  for
staging,  with  which  the  urologist  can:
• evaluate  repercussions  on  the  upper  urinary  tract  and/or
detect  the  presence  of  a  synchronous  urothelial  lesion  in
this  region;
• assess  invasion  of  neighbouring  organs  and  of  the  perivesi-
cal  fat;
• look  for  adenopathy  and/or  metastases  (the  prime
metastatic  sites  being  the  lymph  nodes  and  lungs).
The  sensitivity  and  speciﬁcity  of  diagnosis  of  inﬁltra-
tion  of  the  perivesical  or  perilesional  fat  is  89%  and  95%
respectively,  before  resection.  On  the  other  hand,  when  CT
is  performed  after  trans-urethral  resection  of  the  bladder
(TURB),  staging  can  be  over-estimated  owing  to  inﬂam-
matory  restructuring  of  the  perivesical  fat  [15—17]. This
examination  is  particularly  important  for  guiding  the  urol-
ogist  as  he  performs  the  surgical  ablation,  if  this  has  been
decided  in  a  multidisciplinary  consultation.
CT  only  detects  massive  invasion  of  the  prostate  or  the
seminal  vesicles,  but  does  allow  assessment  of  possible  inva-
sion  of  the  digestive  structures  and  the  existence  of  visceral
(hepatic  and  pulmonary)  metastasis.  Invasion  of  digestive
structures,  in  particular  of  the  sigmoid  colon  or  the  loops  of
the  small  intestine,  by  a  tumour  of  the  dome  is  diagnosed  by
frontal,  sagittal  or  oblique  multiplanar  reformations.  Clini-
cal  signs  and  symptoms  are  an  indication  to  look  for  locations
in  the  brain.
MRI
MRI  is  only  indicated  if  CT  is  contraindicated.  In  practice,
pelvic  MRI  is  only  useful  when  extension  is  suspected  to
neighbouring  organs  (stage  pT3b)  and  has  diagnostic  relia-
bility  of  94%.  However,  MRI  with  injection  is  contraindicated
if  there  is  severe  renal  impairment  with  less  than  30  mL/min
creatinine  clearance,  because  there  is  a  risk  of  nephrogenic
ﬁbrosis  [18,19].  MRI  without  injection  is  possible,  but  its
contribution  amounts  to  less.  MRI  can  also  help  diagnose
invasion  of  the  pelvic  wall  with  bone  lysis.
FDG  PET-CT
There  are  insufﬁcient  data  at  the  present  time  concerning
the  examination  of  urothelial  tumours.
Evaluation  of  lymph  node  extension
The  diagnostic  criterion  for  pelvic  metastatic  adenopathy  is
identical  in  both  CT  and  MRI,  and  based  solely  on  size  (8  mm
in  the  short  axis).
There  is  no  signiﬁcant  difference  between  CT  and  MRI,
with  overall  sensitivity  of  36%  and  speciﬁcity  between  80
and  97%.  Conventional  helical  CT  is  the  most  commonly  used
method,  and  the  most  easily  accessible,  for  detecting  ade-
nomegaly  [20,21].
Mx  Metastases  cannot  be  assessed
M0  No  distant  metastasis
M1  Distant  metastasis
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Boxed  text  2  TNM  classiﬁcation  2002.  Tumours  of
the  upper  urinary  tract.
T Primary  tumour
Tx  Primary  tumour  cannot  be  assessed
T0  No  evidence  of  primary  tumour
Ta  Non-invasive  papillary  carcinoma
Tis  Carcinoma  in  situ
T1  Tumour  invades  subepithelial  connective  tissue
T2  Tumour  invades  the  muscularis  propria
T3  Renal  pelvis: Tumour  invades  beyond  the
muscularis  propria  into  peripelvic  fat  or  the  renal
parenchyma
Ureter:  Tumour  invades  beyond  muscularis  propria
into  periureteric  fat.
T4  Tumour  invades  adjacent  organs,  or  through  the
kidney  into  the  perinephric  fat.
N  Regional  lymph  nodes
Nx  Lymph  nodes  cannot  be  assessed
N0  No  regional  lymph  node  metastasis
N1  Metastasis  in  a  single  lymph  node,  ≤  2  cm  in
greatest  dimension
N2  Metastasis  in  a  single  lymph  node,  >  2  cm  but  not
>  5  cm  in  greatest  dimension  or  multiple  lymph  nodes,
none  >  5  cm  in  greatest  dimension.
N3  Metastasis  in  a  lymph  node  >  5  cm  in  greatest
dimension.
M  Distant  metastases
Mx  Metastases  cannot  be  assessed
M0  No  distant  metastasis
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a  polypoid  lesion  of  between  5  and  10  mm.  In  contrast,  its
sensitivity  falls  to  89%  for  a  polypoid  lesion  smaller  than
5  mm  and  40%  for  one  smaller  than  3  mm.  Flat  undetectable
lesions  pose  the  main  difﬁculty  unless  there  is  massive
inﬁltration  or  they  are  simulating  ureteritis.
MRI  of  the  upper  urinary  tract
MRI  is  indicated  if  there  is  a  contraindication  to  a  CT
examination:  the  rate  of  detection  is  75%  with  injection  of
contrast  agent  for  a  tumour  smaller  than  2  cm.  However,
MRI  with  injection  is  contraindicated  if  there  is  severe  renal
impairment  with  less  than  30  mL/min  creatinine  clearance,
because  there  is  a  risk  of  nephrogenic  ﬁbrosis.
The contribution of imaging to treatment
of  bladder tumours
Using  six  main  clinical  and  pathological  parameters  (grade,
stage,  tumour  size,  previous  rate  of  recurrence,  pres-
ence  of  concomitant  carcinoma  in  situ  [CIS])  and  number
of  tumours),  it  is  possible  to  calculate  the  probability
of  recurrence  and  progression  of  a non  muscle-invasive
tumour  according  to  the  risk  tables  produced  by  the  EORTC
(http://www.eortc.be/tools/bladdercalculator).
Differentiation  classically  depends  on  the  risk  of  recur-
rence  and  progression  (Table  2).
Treatment for  non-muscle invasive bladder
cancer
Initial  treatment:  trans-urethral  resection  of  the
bladder
Apart  from  its  importance  for  diagnosis  and  prognosis,  as
complete  as  possible,  TURB  constitutes  the  ﬁrst  stage  of
treatment.  If  the  lesion  is  a  high-grade,  T1  stage  tumour,
a  large  volume  tumour  and/or  is  multifocal,  or  if  resection
was  incomplete,  it  can  be  more  precisely  staged  by  endo-
scopic  and  histological  re-evaluation  within  a  period  of  four
to  six  weeks,  which  will  improve  screening  of  patients  (and
therefore  their  response)  to  endovesical  treatment,  reduce
Table  2  Risk  for  recurrence  and  progression  of  bladder
tumors  without  inﬁltration  of  the  muscularis.
Low  risk
Ta:  solitary,  low  grade  or  LMP  (grade  1),  diameter  <  3
cm,  no  tumour  recurrence
Intermediate  risk
Ta:  low  grade  or  LMP  (WHO  73),  multifocal  and/or
recurrent
T1:  low  grade  (grade  1—2)
High  risk
Ta:  high  grade  (grade  2/3  and  3)
T1:  high  grade  (grade  2/3  and  3)  or  T1  recurringM1  Distant  metastasis
nitial assessment
rinary  cytology
igh-grade  urinary  cytology  can  strongly  suggest  a  tumour
f  the  upper  urinary  tract,  when  cystoscopy  is  normal,  but
s  less  sensitive,  even  for  high-grade  lesions,  than  it  is  for
umours  in  the  bladder.
ro-CT
ro-CT  is  the  standard  examination  for  exploring  the  upper
rinary  tract  and  has  now  replaced  intravenous  urography
9,22].
Nevertheless,  it  is  strictly  deﬁned  and  involves  acquisi-
ion  in  the  excretory  phase:
multiple  protocols  ranging  from  two  to  four  spiral  acqui-
sitions,  with  slices  of  at  least  1  mm,  before  and  after
injection  of  contrast  agent;
2D  multiplanar  reformations  in  the  excretory  phase,
essential  for  the  upper  urinary  tract  and  the  bladder;
prior  injection  of  a  low  dose  of  diuretic,  essential  for
detecting  a  small  lesion  in  the  pyelocalyceal  cavities  and
for  seeing  the  ureter  better;
initially  high  rate  of  irradiation,  but  decidedly  reduced  on
recent  machines  equipped  with  systems  for  modulating
the  dose  appropriate  to  each  patient.
The  detection  rate  is  satisfactory  when  this  type  of
maging  is  used:  sensitivity  is  96%  and  speciﬁcity  99%  for
CIS  (carcinoma  in  situ)
LMP: low malignancy potential.
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the  frequency  of  recurrence  and  may  delay  progression  of
the  tumour.
Adjuvant  treatment:  endovesical  instillation
In  addition  to  TURB,  treatment  by  endovesical  instillation
may  be  necessary  depending  on  the  risk  of  recurrence
and  progression,  by  either  chemotherapy  (mitomycin  C
[MMC]),  or  immunotherapy  (Bacillus  Calmette  Guérin
[BCG]).
Monitoring non-muscle invasive bladder
cancer
Oncology  monitoring
Because  of  the  risk  of  a  tumour  recurring  and  progres-
sion  of  the  bladder  disease,  the  frequency  of  cystoscopy
examinations  must  be  adapted  for  appropriate  surveillance
depending  on  the  risk  group  [7].  Indeed,  delay  in  diagnosing
and  starting  therapeutic  management  of  high-grade  tumour
recurrence  with  a  strong  possibility  of  muscle  inﬁltration  is
life-threatening  for  the  patient.  CT  has  a  role  particularly  in
looking  for  a  metachronous  UUT-UC.
Monitoring  examinations  are  conducted  according  to  the
risk  group  of  the  bladder  disease  (Table  3).
Treatment for muscle invasive bladder cancer
T2  N0  M0  staging  is  basically  clinical,  because  histology
of  resected  material  is  insufﬁciently  speciﬁc  (minimum  of
T2)  and  neither  local  inﬁltration  of  the  tumour  (T)  nor
invasion  of  lymph  nodes  (N)  can  be  reliably  evaluated
with  a  scan.  The  seriousness  of  invasive  bladder  tumours
entails  the  patient  receiving  clear  information  about  the
risks  of  the  disease  progressing,  the  types  of  treatment
that  can  be  envisaged  and  the  functional  risks  of  radical
surgery.
Cystectomy  is  the  standard  curative  treatment  for  MIBC
but  its  indication  should  be  discussed  with  a  patient  in  his
80s.  The  length  of  time  to  performing  the  surgery  should
not  be  more  than  12  weeks  from  the  time  of  the  diag-
nostic  resection,  or  the  prognosis  could  be  worse  (death
speciﬁcally  from  the  cancer  and  an  overall  greater  risk
of  death).  While  it  is  still  recommended  to  perform  this
procedure  as  open  surgery,  some  teams  are  evaluating
the  advantage  of  mini-invasive  surgery  in  this  indica-
tion.  This  is  nevertheless  contraindicated  if  the  tumour  is
F
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Table  3  Monitoring  examinations  recommended  for  non-musc
rence  and  progression.
Low  risk
Cystoscopy:  at  the  3rd,  6th,  12th  month  then  annually  for  10  ye
Intermediate  risk
Cystoscopy:  at  the  3rd,  6th,  12th  month  then  annually  for  15  ye
Urinary  cytology:  recommended,  associated  with  cystoscopy
Uro-CT:  every  2  years  and  if  cytology  is  positive  or  if  any  sympt
High  risk
Cystoscopy  at  the  3rd,  6th,  9th,  12th  month,  then  every  6  mon
Urinary  cytology  at  the  3rd,  6th,  9th,  12th  month,  then  every  6
Uro-CT  every  2  years  or  if  cytology  is  positive  or  if  any  symptomaging?  295
oluminous,  owing  to  the  risk  of  disseminating  cancer  cells  in
 gaseous  atmosphere  [23]. The  radiologist’s  role  in  describ-
ng  tumour  volume  and  parietal  inﬁltration  is  therefore
rucial.
In  men,  total  cystectomy  removes  the  prostate  and
he  seminal  vesicles.  If  invasion  is  revealed  on  the  supra-
ontanal  biopsy  of  the  prostatic  urethra  and/or  during
xtemporaneous  examination  of  the  urethral  section,
rethrectomy  must  be  performed  in  addition.  Urethral
ecurrence  following  cystectomy  is  a  rare  event  (8%  of
ases),  and  is  observed  usually  in  the  ﬁve  years  following
he  radical  surgery,  hence  the  need  for  constant  monitoring
urinary  cytology,  cystoscopy,  uro-CT).  In  women,  cystec-
omy  usually  takes  with  it  the  complete  uterus  and  urethra,
roducing  an  anterior  pelvectomy.
In  men,  a  neobladder  must  be  systematically  suggested
s  soon  as  the  situation  allows.  The  patient  must  be  properly
creened  and  prepared  and  in  particular  there  must  be  mon-
toring  every  six  months  during  the  ﬁrst  three  years,  then
nnually  thereafter.  A  low-pressure  ileal  or  colonic  neoblad-
er  is  the  standard  treatment,  allowing  urinary  continuity  to
e  re-established.
A  cutaneous  diversion  (Bricker  procedure)  is  performed
n  the  following  situations:
anatomical  impossibility  (a  rare  occurrence  of  which  the
patient  will  have  been  warned  pre-operatively);
tumoral  invasion  of  the  prostatic  urethra  and/or  a  positive
extemporaneous  biopsy  of  the  urethral  section,  leading  to
urethrectomy;
too  great  age  or,  above  all,  inappropriate  mental  state.
In  women,  a  replacement  bladder  is  possible,  but  speciﬁc
riteria  need  to  be  met  [1].  Replacement  enterocystoplasty
n  women  can  mean  that  physical  integrity  and  urinary
unction  can  be  preserved,  with  better  preservation  of  the
ossibility  of  sexual  intercourse.  If  this  is  not  possible,  an
xternal  urinary  diversion  according  to  Bricker  and  conti-
ence  pouches  (Indiana  pouch)  are  the  urinary  systems  most
ften  proposed.
onitoring muscle invasive bladder canceror  MIBC,  monitoring  for  life  is  recommended.  Uro-CT  will
e  performed  every  six  months  for  two  years  then  annually
ollowing  cystectomy  [1].
le  invasive  bladder  cancer  according  to  the  risk  for  recur-
ars  (for  life,  if  nicotine  addiction  continues)
ars  (for  life,  if  nicotine  addiction  continues)
om  indicates  involvement  of  the  upper  tract
ths  in  the  2nd  year,  then  annually  for  life
 months  in  the  2nd  year,  then  annually  for  life
 indicates  involvement  of  the  upper  tract
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onclusion
he  prognosis  for  tumours  of  the  bladder  is  extremely  poor
nce  the  tumour  has  started  to  invade  the  bladder  muscle.
t  this  crucial  time  in  the  disease,  the  radiologist  must  guide
he  clinician  in  the  type  of  management  he  will  offer  the
atient.  Radical  treatment  has  major  consequences  because
t  is  mutilating  and  upsets  an  individual’s  body  image.
TAKE-HOME  MESSAGES
Staging  recommended  for  MIBC:
• Urinary  cytology,  ideally  in  situ.
• Uro-CT  (acquisition  in  excretory  phase).
• Ureteroscopy  with  biopsy  samples.
• Cystoscopy  to  eliminate  a  synchronous  bladder
lesion.
Staging  recommended  for  UUT-UC:
• Urinary  cytology,  ideally  in  situ.
• Uro-CT  (acquisition  in  excretory  phase).
• Ureteroscopy  with  biopsy  samples.
• Cystoscopy  to  eliminate  a  synchronous  bladder
lesion.
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